Antibody persistence following meningococcal ACWY conjugate vaccine licensed in the European Union by age group and vaccine

References

• Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: a systematic review and meta-analysis. Microb Path. 2019;134:103571.
   PubMed Web of Science ®Google Scholar
• Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence. Hum Vaccin Immunother. 2016;12(7):1825–1837.
   PubMed Web of Science ®Google Scholar
• Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20.
   PubMedGoogle Scholar
• Borrow R, Alarcón P, Carlos J, et al., The global meningococcal initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev Vaccines. 16(4): 313–328. 2016.
   PubMed Web of Science ®Google Scholar
• Yazdankhah S. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol. 2004;53(9):821–832.
   PubMed Web of Science ®Google Scholar
• Li J, Shao Z, Liu G, et al. Meningococcal disease and control in China: findings and updates from the Global Meningococcal Initiative (GMI). J Infect. 2018;76(5):429–437.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–36.
   PubMed Web of Science ®Google Scholar
• Ladhani S, Campbell H, Lucidarme J, et al. Invasive meningococcal disease in patients with complement deficiencies: a case series (2008–2017). BMC Infect Dis. 2019;19(1):522.
   PubMed Web of Science ®Google Scholar
• Nadel S, Ninis N. Invasive meningococcal disease in the vaccine era. Front Pediatr. 2018;6:321.
   PubMed Web of Science ®Google Scholar
• Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health. 2007;12(12):1409–1421.
   PubMed Web of Science ®Google Scholar
• Dhillon S, Pace D. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix®): A Review. Drugs. 2017;77(17):1881–1896.
   PubMed Web of Science ®Google Scholar
• Pichichero M. Protein carriers of conjugate vaccines: characteristics, development and clinical trials. Hum Vaccin Immunother. 2013;9(12):2505–2523.
   PubMed Web of Science ®Google Scholar
• Serra L, York L, Balmer P, et al. Meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine: a review of clinical data in adolescents. J Adolesc Health. 2018;63(3):269–279.
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT. Adv Ther. 2013;30(5):431–458.
   PubMed Web of Science ®Google Scholar
• Keshavan P, Pellegrini M, Vadivelu-Pechai K, et al. An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine. Expert Rev Vaccines. 2018;17(10):865–880.
   PubMed Web of Science ®Google Scholar
• Dretler A, Rouphael N, Stephens D. Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development. Hum Vaccin Immunother. 2018;14(5):1146–1160.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–1326. .
   PubMed Web of Science ®Google Scholar
• Balmer P, Borrow R. The immunological basis for immunization series. Module 15: meningococcal disease. World Health Organization; 2010 June. Available from: https://apps.who.int/iris/bitstream/handle/10665/44376/9789241599849_eng.pdf;jsessionid=46EFE2ABBCCE119DF16B5A6568CD8822?sequence=1
   Google Scholar
• Gill C, Ram S, Welsch J, et al. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine. 2011;30(1):29–34.
   PubMed Web of Science ®Google Scholar
• Santos GF, Deck RR, Donnelly J, et al. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol. 2001;8(3):616–623.
   PubMedGoogle Scholar
• Schneider MC, Exley RM, Chan H, et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol. 2006;176(12):7566–7575.
   PubMed Web of Science ®Google Scholar
• Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun. 2009;77(2):764–769.
   PubMed Web of Science ®Google Scholar
• Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccin Immunother. 2019;15(10):2491–2500.
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Tinoco Favila JC, Traskine M, et al. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study. Vaccine. 2018;36(28):4102–4111.
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Kolhe D, et al. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults. Pediatr Infect Dis J. 2015;34(11):1236–1243.
   PubMed Web of Science ®Google Scholar
• Klein NP, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013;32(7):760–767. .
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forstén A, Boutriau D, et al. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012;8(12):1892–1903.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, et al. Antibody persistence to meningococcal serogroups A, C, W and Y in toddlers two years after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate (MenACWY-TT) vaccine as measured by bactericidal antibody assays using rabbit or human complement. Trials Vaccinol. 2014;3:121–126.
   Google Scholar
• Vesikari T, Forsten A, Bianco V, et al. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2015;12(1):132–139.
   Web of Science ®Google Scholar
• Merino Arribas JM, Carmona Martínez A, Horn M, et al. Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants. Pediatr Infect Dis J. 2017;36(4):e98–e107.
   PubMed Web of Science ®Google Scholar
• Perrett K, Snape M, Ford K, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J. 2009;28(3):186–193.
   PubMed Web of Science ®Google Scholar
• Knuf M, Romain O, Kindler K, et al. Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study. Eur J Pediatr. 2013;12(5):601–612.
   Web of Science ®Google Scholar
• Knuf M, Helm K, Kolhe D, et al. Antibody persistence and booster response 68 months after vaccination at 2–10 years of age with one dose of MenACWY-TT conjugate vaccine. Vaccine. 2018;36(23):3286–3295.
   PubMed Web of Science ®Google Scholar
• Huang L, Chiu N, Yeh S, et al. Immunogenicity and safety of a single dose of a CRM-conjugated meningococcal ACWY vaccine in children and adolescents aged 2–18 years in Taiwan: results of an open label study. Vaccine. 2014;32(40):5177–5184.
   PubMed Web of Science ®Google Scholar
• Quiambao B, Jain H, Bavdekar A, et al. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents. Hum Vaccin Immunother. 2016;12(8):2162–2168.
   PubMed Web of Science ®Google Scholar
• Gill C, Baxter R, Anemona A, et al. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin. 2010;6(11):881–887.
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman J, Siegrist C. Glycoconjugate vaccines and immune interference: a review. Vaccine. 2010;28(34):5513–5523.
   PubMed Web of Science ®Google Scholar
• Dagan R, Eskola J, Leclerc C, et al. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Imm. 1998;66(5):2093–2098.
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299(2):173–184.
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis. 2006;43(11):1387–1394.
   PubMed Web of Science ®Google Scholar
• Bona G, Castiglia P, Zoppi G, et al. Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers. Vaccine. 2016;34(29):3363–3370.
   PubMed Web of Science ®Google Scholar
• Beernink PT, Ispasanie E, Lewis LA, et al. A meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and overexpressed factor H binding protein elicits gonococcal bactericidal antibodies. J Infect Dis. 2018;219(7):1130–1137.
   Web of Science ®Google Scholar
• Borja-Tabora C, Montalban C, Memish Z, et al. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis. 2013;13(1):116. .
   PubMed Web of Science ®Google Scholar
• Davis K, Ford K, Craik R, et al. The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study. Trials. 2019;20(1):455.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
   PubMed Web of Science ®Google Scholar
• White M, Idoko O, Sow S, et al. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials. Lancet Infect Dis. 2019;19(3):327–336.
   PubMed Web of Science ®Google Scholar
• Yaro S, Njanpop Lafourcade B, Ouangraoua S, et al. Antibody persistence at the population level 5 Years after mass vaccination with meningococcal serogroup A conjugate vaccine (PsA-TT) in Burkina Faso: need for a booster campaign? Clin Infect Dis. 2018;68(3):435–443. .
   Web of Science ®Google Scholar
• Peterson J, Hedrick J, Pan J, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered in adults 18–55 years of age. Open Forum Infect Dis. 2019;6(Suppl 2):S957–S957.
   Google Scholar
• Sáez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, et al. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. Hum Vaccin Immunother. 2018;14(5):1161–1174.
   PubMed Web of Science ®Google Scholar